Ardelyx, Inc. (ARDX)

NGM – Real vaqt narxi. Valyuta: USD

5.48

-0.21 (-3.69%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

5.48

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 6:11 PM EDT

12.03.2026

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, announced the recipients of the 2026 Derek Forfang Patient Advocate Award: Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts.

09.03.2026

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment

04.03.2026

Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2026 Global Healthcare Conference Location: Miami, FLPresentation: Tuesday, March 10 at 4:20 p.m.

01.03.2026

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Michael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share. The sale represented 2.19% of Raab's direct holdings at the time of the transaction.

24.02.2026

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

DAYTONA BEACH, Fla. and WALTHAM, Mass.

21.02.2026

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

20.02.2026

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.

Videolar

No Data

There is no data to display

Press-relizlar

12.03.2026

Ardelyx, Inc. (ARDX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ardelyx, Inc. (ARDX)

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Videolar

No Data

Press-relizlar

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Videolar

No Data

Press-relizlar

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update